University of Minnesota Medical School researchers explored the possible biological mechanisms that could explain the association between being overweight or obese prior to pregnancy and the increased risk of acute lymphoblastic leukemia in children.
New findings by the ACS found cumulative economic losses from cigarette smoking topped $891 billion in 2020, or 4.3% of the U.S. Gross Domestic Product. The economic loss significantly outpaced the cigarette industry’s $92 billion revenue by nearly a ten-to-one ratio. The study was published today in the journal The Lancet Public Health.
From March through December 2020, more than 16,000 cancer deaths were due to complications of COVID-19 in the U.S., according to a new study led by researchers at the American Cancer Society.
Moffitt Cancer Center has conducted the first prospective study to investigate genomic biomarkers associated with aggressive disease in African American men with prostate cancer, a population with disparities in incidence and mortality.
Former smokers who stick to a healthy lifestyle have a lower risk of dying from all causes than those who don’t engage in healthy habits, according to a study by researchers at NCI. The reduced risk of dying was observed for specific causes, including cancer.
Researchers have compiled a comprehensive genetic architecture atlas for mutant RAS genes in human cancers.
Through extensive single-cell analysis, researchers at MD Anderson Cancer Center have created a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, highlighting previously unappreciated roles these immune cells play in tumor development and treatment outcomes.
Lynparza (olaparib) showed clinically meaningful survival benefit as first line therapy in certain patients with ovarian cancer, according to long-term data.
Southwest Oncology Group researchers have found that starting Keytruda (pembrolizumab) before surgery instead of waiting until after surgery significantly improves the outlook for patients with stage III-IV melanoma.
In an international, multicenter phase II clinical trial led by MD Anderson Cancer Center, 63.3% of patients with stage II–IV cutaneous squamous cell carcinoma saw their tumors nearly or completely disappear when treated with immunotherapy before surgery.
